How to Read a PDUFA Date: What Every Biotech Investor Needs to Know Before the FDA Deadline

A PDUFA date, Prescription Drug User Fee Act date, is the FDA's self-imposed deadline for completing review of a new drug application. It is the single most important date in biotech investing. No other calendar event concentrates investor attention, analyst coverage, and trading volume in the same way. Understanding what a PDUFA date actually represents, what can happen at it, and what the lead-up filing sequence looks like is foundational knowledge for anyone trading biotech stocks.

What a PDUFA Date Actually Is

When a pharmaceutical or biotech company submits a New Drug Application (NDA) or a Biologics License Application (BLA) to the FDA, the agency has a statutory obligation under the Prescription Drug User Fee Act to review the application within a defined timeframe. The deadline, the PDUFA date, is set at the time the FDA accepts the application for review.

Standard review: 12 months from submission. Priority Review (granted for drugs that address unmet medical needs): 6 months. The FDA accepts or declines to accept an NDA/BLA within 60 days of submission, a filing known as the "filing decision." Once accepted, the PDUFA date is fixed and public.

The FDA does not always meet its PDUFA date. It can request a three-month extension if it needs additional time to review a late-cycle amendment, a significant data submission the company makes during the review period. If an AdCom meeting is required and wasn't initially planned, the FDA may also push the date. Extensions get an 8-K filing from the company typically the same day the FDA communicates them.

The Filing Sequence Before a PDUFA Date

Reading the SEC filing history before a PDUFA date gives you a clear picture of how the review is progressing. The key milestones to watch:

• NDA/BLA Submission (8-K, Item 8.01): The initial submission. The company announces the filing and the indication. No PDUFA date yet, that comes after acceptance.
• FDA Acceptance (8-K): The FDA has accepted the application for review and set the PDUFA date. This is the event that creates the investable catalyst. The PDUFA date is now public.
• AdCom announcement (8-K or press release): If the FDA schedules an Advisory Committee meeting, this is disclosed as a separate event. AdComs are not required, the FDA holds them when it wants external expert input on a close or complex decision. An AdCom vote does not bind the FDA, but an unfavorable AdCom vote (especially a decisive one) is a strong negative predictor for approval.
• Complete Response Letter or Approval (8-K): The outcome. A Complete Response Letter (CRL) means the FDA will not approve the application in its current form, the company must respond to specific deficiencies. An approval letter means the drug can be commercially launched.

What Happens at the PDUFA Date: Three Outcomes

1. Approval. The FDA grants approval for the labeled indication. The stock typically opens up sharply, the magnitude depends on how much of the approval was priced in. A first-in-class drug with strong Phase 3 data and no AdCom uncertainty often sees muted approval-day moves because the positive outcome was already consensus. A drug with a messy AdCom vote or manufacturing concerns that gets approved anyway can produce outsized moves.

2. Complete Response Letter (CRL). The FDA refuses approval and specifies what the company must do before resubmission. CRLs typically cite clinical (need more data or a different trial), chemistry/manufacturing/controls (CMC issues), or labeling concerns. The stock usually drops sharply. The severity of the drop depends on whether the market had priced in approval and how addressable the cited deficiency is. A CMC-only CRL is generally easier to recover from than a clinical-only CRL requiring a new Phase 3 trial, that can be years and hundreds of millions of dollars.

3. Extension or delay. The FDA requests a three-month extension and sets a new date. This is a mixed signal, the FDA needs more time, which can mean they're working through a complex question rather than heading to a CRL. Extensions don't uniformly predict CRLs, but they create uncertainty and typically move the stock down on the news. The new date becomes the catalyst.

How to Use PDUFA Dates as an Investment Signal

Experienced biotech investors use PDUFA dates as anchors for position sizing, not as binary bets. The basic framework:

• Know the base rate. FDA approval rates for NDAs and BLAs that reach PDUFA date, meaning applications that weren't withdrawn before the deadline, run 85–90% historically. But this aggregate rate includes drugs with very different risk profiles at the time of the PDUFA date. An application with a favorable AdCom, clean Phase 3 data, and no manufacturing flags has a much higher conditional probability than one where the AdCom voted 8-4 against and the FDA requested a late-cycle amendment.
• Read the AdCom transcript, not just the vote count. FDA advisory committees vote on specific questions, and the framing matters. A 12-4 vote against "as currently labeled" can still lead to approval with a label modification. A 10-6 vote in favor with three panelists citing safety signals can lead to a CRL. The transcript gives you the argumentation; the vote count is a summary.
• Watch for late-cycle amendments (LCA). A Late-Cycle Amendment is a significant data submission the company makes after the NDA/BLA is filed but before the PDUFA date. The FDA must notify the company if an LCA triggers a potential 3-month extension. Companies disclose LCAs in 8-Ks. An LCA is not automatically negative, sometimes it's additional safety data the FDA requested and the company is providing on schedule. But it is additional complexity in the review, and complexity increases the probability of a CRL.
• Check the dilution picture before taking a position. Pre-revenue biotechs approaching a PDUFA date are often low on cash. Many companies run a secondary offering or ATM program in the months before the decision to extend their cash runway past the binary event. Entering a PDUFA position in a stock that has already sold 30% of its float in the past six months means you're paying for the dilution impact on top of the binary risk. BiotechSign's dilution risk score specifically accounts for this.

The Difference Between Priority Review and Standard Review

Priority Review designation shortens the review timeline from 12 months to 6 months. It's granted for drugs that treat serious conditions and offer advantages over available therapies. The designation doesn't change the approval standard, the drug still has to meet the same efficacy and safety bar. But the compressed timeline concentrates the catalyst sooner, limits the window for late-cycle complications, and is generally considered a positive signal about how the FDA views the application.

Breakthrough Therapy Designation (BTD) is separate from Priority Review but often accompanies it. BTD means the FDA has agreed to provide intensive guidance to the company throughout the development process, it's a signal of close FDA engagement, which historically correlates with higher approval probabilities. Checking whether a drug has BTD is part of any serious PDUFA date pre-analysis.

Reading the 8-K on Decision Day

When the FDA decision comes out, typically in the morning before market open, the company files an 8-K within four business days, but in practice the press release hits the same day. The 8-K is what matters legally, but the press release is what moves the stock. What to look for in the text:

• For approvals: the exact labeled indication and any REMS (Risk Evaluation and Mitigation Strategy) requirements. A narrow label (limited to a subpopulation smaller than the market had assumed) can turn a nominal approval into a negative catalyst.
• For CRLs: the specific categories of deficiency cited. "Chemistry, manufacturing, and controls" vs. "clinical" vs. "labeling", these have very different implications for resubmission timelines and probability.
• For extensions: the new PDUFA date and any stated reason. If the company says the extension was triggered by a late-cycle amendment they submitted, the extension is their responsibility. If the FDA extended on its own initiative, it means the agency identified something during review that needs more time.

BiotechSign's calendar tracks PDUFA dates across all publicly traded biotechs with active NDAs and BLAs, linked to the SEC filing history for each application. The catalyst score weights upcoming PDUFA events alongside AdCom schedules, clinical data readouts, and insider activity, giving you a composite signal rather than a single event to trade.